18-Month Shelf Life Strengthens SPONTAN Commercialisation
Filed with ASX · · 2 pages · English
® ® • SPONTAN achieves 18-month shelf life under ICH conditions, surpassing current commercial distribution requirements. • Confirms commercial-scale manufacturing and distribution capabilities across Australia. • Supports strategic discussions with leading pharmaceutical partners. • Ongoing stability studies provide a clear regulatory pathway for further shelf-life extensions. ® LTR Pharma Limite
Earlier from LTR Pharma
- SPONTAN 5x Faster Onset Validated in EU Journal
- LTP Completes Extractables Study Milestone for SPONTAN
- Urological Expert Appointed to LTR Scientific Advisory Board
- SPONTAN Expands Patient Access via National Pharmacy Network
- LTR Signs Collaborative Agreement to Develop OMD Nasal Spray
Later from LTR Pharma
- SPONTAN Case Series - Strong Post-Prostatectomy Results
- Appendix 4E and Annual Report to Shareholders
- FY25 Results Announcement
- LTR Pharma secures 33% ownership in LevOmega Pty Ltd
- LTR increases LevOmega stake to 43% with $1m investment
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma